These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26056464)

  • 1. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence.
    Prud'homme M; Cata R; Jutras-Aswad D
    Subst Abuse; 2015; 9():33-8. PubMed ID: 26056464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol in the context of substance use disorder treatment: A systematic review.
    Paulus V; Billieux J; Benyamina A; Karila L
    Addict Behav; 2022 Sep; 132():107360. PubMed ID: 35580370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.
    Calpe-López C; García-Pardo MP; Aguilar MA
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31315244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol and substance use disorder: Dream or reality.
    Karimi-Haghighi S; Razavi Y; Iezzi D; Scheyer AF; Manzoni O; Haghparast A
    Neuropharmacology; 2022 Apr; 207():108948. PubMed ID: 35032495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.
    Razavi Y; Keyhanfar F; Shabani R; Haghparast A; Mehdizadeh M
    Iran J Pharm Res; 2021; 20(4):152-164. PubMed ID: 35194436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
    Elsaid S; Kloiber S; Le Foll B
    Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: A systematic review.
    Rodrigues LA; Caroba MES; Taba FK; Filev R; Gallassi AD
    Pharmacol Biochem Behav; 2020 Sep; 196():172982. PubMed ID: 32645315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.
    Navarrete F; García-Gutiérrez MS; Gasparyan A; Austrich-Olivares A; Manzanares J
    Front Pharmacol; 2021; 12():626010. PubMed ID: 34093179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
    Osborne AL; Solowij N; Weston-Green K
    Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
    Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
    Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicians' Guide to Cannabidiol and Hemp Oils.
    VanDolah HJ; Bauer BA; Mauck KF
    Mayo Clin Proc; 2019 Sep; 94(9):1840-1851. PubMed ID: 31447137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.
    Gonzalez-Cuevas G; Martin-Fardon R; Kerr TM; Stouffer DG; Parsons LH; Hammell DC; Banks SL; Stinchcomb AL; Weiss F
    Neuropsychopharmacology; 2018 Sep; 43(10):2036-2045. PubMed ID: 29686308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus.
    Luján MÁ; Castro-Zavala A; Alegre-Zurano L; Valverde O
    Neuropharmacology; 2018 Dec; 143():163-175. PubMed ID: 30273593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.
    Turna J; Syan SK; Frey BN; Rush B; Costello MJ; Weiss M; MacKillop J
    Alcohol Clin Exp Res; 2019 Apr; 43(4):550-563. PubMed ID: 30698831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review.
    Lo LA; MacCallum CA; Nanson K; Koehn M; Mitchell I; Milloy MJ; Walsh Z; Fehr F
    Can J Psychiatry; 2023 Aug; 68(8):557-571. PubMed ID: 37376827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.
    Nona CN; Hendershot CS; Le Foll B
    Exp Clin Psychopharmacol; 2019 Aug; 27(4):359-369. PubMed ID: 31120285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol as a potential treatment for psychosis.
    Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
    Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
    Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release.
    Gobira PH; Vilela LR; Gonçalves BD; Santos RP; de Oliveira AC; Vieira LB; Aguiar DC; Crippa JA; Moreira FA
    Neurotoxicology; 2015 Sep; 50():116-21. PubMed ID: 26283212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.